New NASDAQ Alert [Inside]

AwesomeStocks Don’t want emails from us anymore? Click [here]( to unsubscribe. Hello! New Alert: PetVivo Holdings, Inc. (NASDAQ: PETV) PETV is our brand new NASDAQ hidden gem. PETV has a history of experiencing significant upside in a short period of time. If PETV rallies above its 50 day moving average of 1.13, it could be positioned for a big breakout opportunity. PETV has a 200 day moving average of 1.49, 30% above Friday’s close. In addition, the company announced multiple accomplishments recently. PETV is NASDAQ listed “emerging biomedical device company”. PETV is “focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals”. More people own pets today than ever before. - “As of 2024, 66% of U.S. households (86.9 million homes) own a pet”, up from “56% in 1988”. From companionship to emotional support, “pets are a vital part of their owners’ lives”. In fact, according to data from Forbes, “97% of pet owners consider their pets to be a part of their family”. PETV’s “strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way”. A “key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics”. PETV has a “robust pipeline of products for the treatment of animals and people”. Importantly, a “portfolio of twenty-one patents protects the Company's biomaterials, products, production processes and methods of use”. The company’s “lead product SPRYNG™ with OsteoCushion™ technology, a veterinarian-administered, intraarticular injectable medical device for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses, is currently available for commercial sale”. “Osteoarthritis, also known as degenerative joint disease, is a progressive disease of the joints fueled by chronic inflammation.” Sadly, “In the United States, about 14 million adult dogs are affected with osteoarthritis, making it a top health concern for owners”. According to another stat from the Morris Animal Foundation, “The exact numbers for cats remain uncertain, but 90% of cats over 12 years old exhibit X-ray evidence of osteoarthritis.” PETV has announced multiple accomplishments recently that could be growth catalysts. In December, the company announced: - “PetVivo Holdings, Inc. Achieves National Distribution of Spryng™ to More than 600 Veterinary Clinics in 49 States” In addition, the company also announced: “PetVivo Holdings, Inc. Achieves Distribution Milestone Surpassing 4500 Syringes of Spryng™ in 2023” As the company further explained in this press release: “Veterinarian enthusiasm for Spryng is higher than ever making this the biggest year yet for Spryng distribution.” Furthermore: “The distribution of syringes of Spryng is an increase in excess of sixty percent from the previous year.” Earlier this year, the company also announced: “PetVivo Recieves Notice of Allowance from United States Patent and Trademark Office for Key Patent Application” As the company further explained: “The broad scope of the issued claims in this patent, entitled “Protein Biomaterials and Biocoacervates and Methods of Making and Using Thereof” provides protection for a broad range of proprietary products, including the biocompatible sponge-like particles used in PetVivo’s signature product, Spryng™ with OsteoCushion™ Technology.” Here are some of the company’s comments from this press release: “We are incredibly excited about the current expansion of our intellectual property portfolio due to the allowance of another patent that further covers and protects our innovative proprietary technology," said John Lai Chief Executive Officer of PetVivo Holdings, Inc. “One of PetVivo’s primary initiatives is to pursue, capture and enforce our proprietary intellectual property assets. This patent increases the scope of our patent claims, thereby expanding our competitive advantage in the commercialization of products used in the treatment of humans and companion animals.” Plus, the company announced: “PetVivo Holdings, Inc. Announces Release of Clinical Study Results Involving Canine Tolerance to Intra-articular Injections of Spryng™ with OsteoCushion™ Technology” As the company explained: “The data provided from the dogs enrolled in this study demonstrates the excellent safety profile of Spryng when injected IA into 40 joints (10 each, stifle, elbow, shoulder, hip) across 20 individual dogs.” In February, the company announced: “PetVivo Holdings, Inc. Announces Release of Clinical Study Results Involving Feline Tolerance to Intra-articular Injections of Spryng™ with OsteoCushion™ Technolgoy” Here are some of the company’s comments from this press release: “We are pleased to have the release of the final results of this Spryng tolerance study as this data demonstrates the safety of our veterinary medical device, Spryng, when injected into the joints of cats,” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “We continue to strive to provide data demonstrating that Spryng is a viable tool to use in the management of joint related afflictions found in companion animals, such as cats.” In addition, the company announced: “Clinical Study Results Involving Spryng, a PetVivo Holdings, Inc. Product, Presented at the Veterinary Orthopedic Society Annual Conference in Lake Tahoe, California” “The dogs enrolled in this study had been diagnosed with unilateral or bilateral coxofemoral joint osteoarthritis. Nine dogs have completed the study to date. At day 84, 7 of 9 patients (77.8%) had a greater than 3-point reduction in total CBPI score, and 7 of 9 patients (77.8%) had improved hip extension on goniometry. All 9 patients (100%) had improved visual lameness scores and quality of life assessments In summary, this study demonstrates that Spryng™ may be a viable alternative for medical management of dogs with coxofemoral joint osteoarthritis.” Most recently, the company announced: “PetVivo Reports Third Quarter of Fiscal 2024 Financial Results” Here are some of the company’s comments from this announcement: ““We are excited about the progress the Company has made this past quarter, including the addition of Covetrus North America, LLC. (Covetrus), to distribute our products beginning in January 2024,” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. The addition of the vast distribution resources offered by Covetrus to the distribution resources offered by our other distribution partner, MWI Animal Health, arms PetVivo with the two largest animal health industry distributors in the United States selling Spryng™ with OsteoCushion™ Technology” In addition, just this morning, the company announced: - “Petvivo Holdings, Inc. To Exhibit At The Ivapm Pain Management Forum In Indianapolis, Indiana” PETV could be positioned to experience high growth. Make sure to do your own due diligence. Sources: [Forbes]( [Morris]( [Presentation]( [PR1]( [PR2]( [PR3]( [PR4]( [PR5]( [PR6]( [PR7]( [PR8]( [PR9]( [PR10]( [PR11]( [Website]( [Chart]( Happy Trading! AwesomeStocks Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose. DISCLAIMER You should read and understand this disclaimer in its entirety before joining the website or email/blog list of AwesomeStocks.com (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help. The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete. The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete. Owners and operators of the Publisher have been compensated ten thousand dollars by bank wire transfer on 4/5/24 for the distribution of this advertisement about PETV dated 4/8/24. The Publisher and its owners and operators hold no stocks or bonds in companies discussed in the Advertisement. Owners and operators of the Publisher own several newsletters, therefore you may receive multiple publications and emails featuring companies at different or the same time. You are receiving this report/release because you subscribed to receive it at our website or through a third-party site. All our newsletters include an "unsubscribe" link, and you can remove yourself at any time from our newsletters by clicking on that "unsubscribe" link. You can also contact us at info@AwesomeStocks.com to change your information at any time. By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: www.AwesomeStocks.com/Disclaimer and www.AwesomeStocks.com/Privacy-Policy By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink. Our records indicate that {EMAIL} requested and confirmed to be added to AwesomeStocks.com on March 5, 2023. [Click Here To Unsubscribe]( 6020 Bent Pine Dr Orlando Florida 32822 USA [Unsubscribe]( | [Change Subscriber Options](